On April 28, the FDA accepted MAPS’ study protocol. That same day, MAPS submitted the protocol to be reviewed by NIDA and the Public Health Service, bothpart of HHS. This additional review is required solely because of NIDA’s monopoly. Researchers do not need approval from NIDA or the PHS when initiating studies into the therapeutic uses of more controversial compounds, such as MDMA and LSD.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.